Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, Cohen S, Falk P, Fung H, Kirschbaum M, Krishnan A, Kogut N, Molina A, Nakamura R, O'Donnell M, Popplewell L, Pullarkat V, Rosenthal J, Sahebi F, Smith E, Snyder D, Somlo G, Spielberger R, Stein A, Sweetman R, Zain J, Forman S.

Biol Blood Marrow Transplant. 2005 Apr;11(4):307-13.

2.

[Prophylaxis and treatment of chronic graft versus host disease].

Huang K, Li Y, Huang SL, Fang JP, Zhou DH, Chen C.

Zhonghua Er Ke Za Zhi. 2005 Mar;43(3):174-7. Chinese.

PMID:
15833186
3.

Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.

Busca A, Saroglia EM, Lanino E, Manfredini L, Uderzo C, Nicolini B, Messina C, Rabusin M, Miniero R.

Bone Marrow Transplant. 2000 May;25(10):1067-71.

PMID:
10828867
4.

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.

Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J.

Ann Hematol. 2005 Oct;84(10):681-5. Epub 2005 Jul 7.

PMID:
16001244
5.

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.

Takami A, Mochizuki K, Okumura H, Ito S, Suga Y, Yamazaki H, Yamazaki M, Kondo Y, Asakura H, Nakao S.

Int J Hematol. 2006 Jan;83(1):80-5.

PMID:
16443558
6.

Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.

Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, Lee KB.

Eur J Haematol. 2004 Jul;73(1):56-61.

PMID:
15182339
7.

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1576-82. doi: 10.1016/j.bbmt.2015.04.023. Epub 2015 May 16.

8.

Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.

Villanueva FN, Pérez-Simón JA, Silva FF, Caballero-Velázquez TT, Sánchez-Guijo FF, Cañizo CC, Vázquez LL, Caballero DD, San Miguel JF.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1331-6. doi: 10.1016/j.bbmt.2009.05.018. Epub 2009 Jul 22.

9.

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.

Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.

Biol Blood Marrow Transplant. 2004 Apr;10(4):246-58.

10.
11.

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.

Mookerjee B, Altomonte V, Vogelsang G.

Bone Marrow Transplant. 1999 Sep;24(5):517-20.

PMID:
10482936
12.

Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.

Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G.

Bone Marrow Transplant. 2005 Jun;35(11):1089-93.

PMID:
15821769
13.
14.

Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD).

Castagna L.

Haematologica. 2003 Aug;88(8):ELT28; author reply ELT29. No abstract available.

15.

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I.

Transplantation. 1997 Dec 27;64(12):1755-60.

PMID:
9422416
16.

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.

Basara N, Blau WI, Römer E, Rudolphi M, Bischoff M, Kirsten D, Sanchez H, Günzelmann S, Fauser AA.

Bone Marrow Transplant. 1998 Jul;22(1):61-5.

PMID:
9678797
17.

Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.

Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF; Grupo Español de Trasplante Hematopoyético (GETH).

Biol Blood Marrow Transplant. 2008 Jun;14(6):664-71. doi: 10.1016/j.bbmt.2008.03.007.

18.

A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.

Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R.

Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505.

19.

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.

Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE.

Transplantation. 2000 Mar 15;69(5):834-41.

PMID:
10755536
20.

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.

Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.

Transplantation. 2007 Feb 27;83(4):417-24.

PMID:
17318074

Supplemental Content

Support Center